UPDATED May 18, 2024
Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
---|---|---|---|---|---|---|---|---|---|---|---|
ISI | ₪13.96 | 0.07% | 5.4% | ₪851.3m | n/a | PE49.1x | E72.2% | n/a | Capital Goods | ||
BWAY | ₪9.95 | -4.0% | 253.8% | ₪332.7m | n/a | PS2.6x | E147.3% | n/a | Healthcare | ||
KMDA | ₪19.77 | -3.2% | 11.4% | ₪1.1b | n/a | PE24.6x | E25.7% | n/a | Pharmaceuticals & Biotech | ||
ALAR | ₪9.44 | -8.7% | 1,218.6% | ₪631.4m | n/a | PS6.2x | E99.5% | n/a | Software |